2012/10/24 15:50 2012/10/24 15:50
2012/10/19 09:19 2012/10/19 09:19
암 환자가 해마다 늘고 있습니다.

그런데 암 환자의 대부분은 극심한 통증에 시달리고 있습니다.

최근 암 환자들의 고통을 줄여줄 클리닉이 생겼습니다.

지난해 대장암에 걸려 항암 치료 중인 60대 남성입니다.

시도 때도 없이 찾아오는 극심한 통증이 너무 괴롭기만 합니다.



[서동현(60)/대장암 환자 : 이번에는 통증이 치아 쪽으로 오더라고요. 이가 다 솟는 것처럼 아팠어요.]


그러나 통증을 줄여주는 약물치료로 통증이 거의 사라졌습니다.


[서동현(60)/대장암 환자 : 기분이 좋고, 앞으로도 계속 좋아질 거라고 믿고 있습니다.]



한국호스피스와 완화의료학회가 암환자 3천여 명을 조사한 결과 67%가 통증이 심해서 일상생활에 지장이 있다고 답했습니다.

특히 30%의 환자는 극심한 통증으로 아무 일도 할 수 없다고 말했습니다.


그런데 지난달 연세대 세브란스병원에 암환자들의 고통을 줄여 줄 암성 통증클리닉이 문을 열었습니다.


[신상준/연세대의대 종양내과 교수 : 통증을 줄이면서 삶의 질이 높아 질 수 있음에도 불구하고 그것을 못해가지고 질이 떨어진다던지 치료가 상당히 나빠지는 그런 결과들이 일어날 수 있기 때문에 그것을 예방하기 위해서 저희들이 이런 것들을 이제 준비하게 되는 거죠.]



암성 통증클리닉에서는 제일 먼저 환자들의 통증의 정도를 알아봅니다.

이 점수를 통해 통증 관리가 이뤄집니다.



[안수림/연세대의대 종양내과 통증전담 간호사 : 통증에도 점수가 있습니다. 각 환자분들의 통증을 평가해서 환자분들의 통증 강도에 따라 진통제 용량을 조절해드리고, 복용법을 상담해 드리고 있습니다.]


올해 5월 척추종양에 걸려 항암 치료를 받고 있는 50대 여성입니다.

극심한 통증을 참을 수 없어 통증클리닉을 찾았습니다.


[김 모씨(53)/척추종양 환자 : 이렇게 처방을 잘해주셔서 더 많이 좋아졌다고 생각해요. 좋아졌습니다.]



치료를 받은 뒤 통증의 강도가 10 이상에서 6 이하로 떨어졌습니다.

암환자의 통증은 조절만 잘하면 삶의 질뿐만 아니라 치료성적도 좋아질 수 있습니다.

따라서 암환자들의 통증을 전문적으로 관리할 시스템이 마련돼야 한다고 전문의사들이 강조합니다.
2011/05/20 15:16 2011/05/20 15:16


사용자 삽입 이미지











교육 및 임상 경력

1998.3-1999.2:  서울  아산병원  인턴
2002.5-2006.2:  영남대학  병원  전공의(내과)
2006.3-2008.2:  연세대  의대  내과학교실  연구강사
2008.3-2009.2:  연세대  의대  내과학  교실  전임강사
2009.3-2013.2:  연세대  의대  내과학  교실  조교수
2012.3-2014.2:  미국  MD  Anderson  Cancer  Center  연수
2013.3-현재    :  연세대  의대  내과학  교실  부교수

학술관련경력

대한내과학회
대한암학회
한국 임상암학회
미국암학회

주요 관심분야

대장암 (소화기암)의 항암약물치료

학력사항

영남대학교 의과대학 (1998)
영남대학교 석사 (2005)
연세대학교 박사 (2011.08)



 

 

논문

Kim SH, Cho BC, Choi HJ, Chung KY, Kim DJ, Park MS, Kim SK, Chang J, Shin SJ et al: The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC. Lung Cancer Dec 21, 2007

Choi HJ, Cho BC, Shin SJ, et al: Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. Cancer Chemother Pharmacol 61:309-13, 2008

Cho BC, Im CK, Park MS, Kim SK, Chang J, Park JP, Choi HJ, Kim YJ, Shin SJ et al: Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib, J Clin Oncol, 2007, 2528-33

Jeung HC, Rha SY, Shin SJ, et al: A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status. Br J Cancer 97:458-63, 2007

Shin SJ, Jeung HC, Ahn JB, et al: Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. Cancer Chemother Pharmacol, 2007

Sohn JH, Choi HJ, Chang J, Shin SJ et al: A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer. Lung Cancer 54:365-70, 2006

Lee KH, Shin SJ, Kim KO, et al: Relationship between E-cadherin, matrix metalloproteinase-7 gene expression and clinicopathological features in gastric carcinoma. Oncol Rep 16:823-30, 2006

Kim KO, Lee HY, Chun SH, Shin SJ et al: Clinical overview of extrapulmonary small cell carcinoma. J Korean Med Sci 21:833-7, 2006

Shin SJ, Kim KO, Kim MK, et al: Expression of E-cadherin and uPA and their association with the prognosis of pancreatic cancer. Jpn J Clin Oncol 35:342-8, 2005

Shin SJ, Chun SH, Kim KO, et al: Myelodysplastic syndrome with complex karyotypic abnormality in a patient with Waldenstrom's acroglobulinemia after sequential treatment with chlorambucil and fludarabine. Jpn J Clin Oncol 35:622-5, 2005

Shin SJ, Chun SH, Kim KO, et al: The efficacy of paclitaxel and cisplatin combination chemotherapy for the treatment of metastatic or recurrent gastric cancer: a multicenter phase II study. Korean J Intern Med 20:135-40, 2005

Shin SJ, Kim MK, Lee KH, Hyun MS,Bae SH, Ryoo HM, et al: The Efficacy of Docetaxel and Cisplatin Combination Chemotherapy for the Treatment of Advanced Gastric Cancer after Failing to 5-FU based Chemotherapy: a Single-Center Phase II Study. Cancer Research and Treatment, 2004


Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib
JOURNAL OF CLINICAL ONCOLOGY 25 18:2528~2533,2007


A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status
BRITISH JOURNAL OF CANCER 97:458~463,2007


Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy
ACTA ONCOLOGICA 46 4:547~549,2007


Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer
Radiotherapy And Oncology 87:361~366,2008


Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer
Cancer Chemotherapy And Pharmacology 61:157~165,2008


The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer
Cancer Chemotherapy And Pharmacology 61:75~81,2008


Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy
Cancer Chemotherapy And Pharmacology 61:309~313,2008


Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer
Annals Of Oncology 19 6:1135~1140,2008


The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC
Lung Cancer 60 3:393~400,2008


Mobilized CD34(+) cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer
Cancer Letters 270 2:269~276,2008


Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials
CANCER CHEMOTHERAPY AND PHARMACOLOGY 63 5:919~927,2009


Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer
International Journal Of Oncology 34 3:787~796,2009


Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck
CANCER CHEMOTHERAPY AND PHARMACOLOGY 65 1:27~32,2009


Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in korea
Cancer Research And Treatment 41 2:67~72,2009


Brain metastases from hepatocellular carcinoma: prognostic factors and outcome
Journal Of Neuro-Oncology 91 3:307~313,2009


Benefits of Recurrent Colonic Stent Insertion in a Patient with Advanced Gastric Cancer with Carcinomatosis Causing Colonic Obstruction
Yonsei Medical Journal 50 2:296~299,2009


Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients
Cancer Letters 288 1:124~132,2010


Two Dosages of Oral Fluoropyrimidine S-1 of 35 and 40 mg/m(2) bid: Comparison of the Pharmacokinetic Profiles in Korean Patients with Advanced Gastric Cancer
JAPANESE JOURNAL OF CLINICAL ONCOLOGY 40 1:29~35,2010


A Phase II Study of a Combined Biweekly Irinotecan and Monthly Cisplatin Treatment for Metastatic or Recurrent Gastric Cancer
American Journal of Clinical Oncology-Cancer Clinical Trials 33 1:56~60,2010


Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer
Radiotherapy And Oncology 95 3:303~307,2010


Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 136 3:387~394,2010


A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer
Investigational New Drugs 28 5:650~658,2010


Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: A phase II trial
Lung Cancer 70 1:77~81,2010


The role of adjuvant pelvic radiotherapy in rectal cancer with synchronous liver metastasis: a retrospective study
RADIATION ONCOLOGY 5:75~75,2010


A Case of Combined Hepatocellular-Cholangiocarcinoma with Favorable Response to Systemic Chemotherapy
Cancer Research and Treatment 42 4:235~238,2010


Brain metastases from colorectal carcinoma: prognostic factors and outcome
JOURNAL OF NEURO-ONCOLOGY 101:49~55,2011


A Randomized Phase 2 Study of Docetaxel and S-1 Versus Docetaxel and Cisplatin in Advanced Gastric Cancer With an Evaluation of SPARC Expression for Personalized Therapy
CANCER 117 10:2050~2057,2011


Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer
ANTI-CANCER DRUGS 22 8:801~810,2011


Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles
ONCOLOGY 80 5-6:395~405,2011


Comparison of Long-Term Outcome between Doublet and Triplet Neoadjuvant Chemotherapy in Non-Metastatic Osteosarcoma of the Extremity
ONCOLOGY 80 1-2:107~117,2011


Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer
INVESTIGATIONAL NEW DRUGS 29 5:1073~1080,2011


Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer
CANCER CHEMOTHERAPY AND PHARMACOLOGY 68 0:991~999,2011


Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 81 3:669~676,2011


Upfront systemic chemotherapy and preoperative short-course radiotherapy with delayed surgery for locally advanced rectal cancer with distant metastases
RADIATION ONCOLOGY 6 0:99~99,2011


Comparison of Diffusion-Weighted MRI and MR Volumetry in the Evaluation of Early Treatment Outcomes After Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer
JOURNAL OF MAGNETIC RESONANCE IMAGING 34 3:570~576,2011


Efficacy of Oxaliplatin-Based Chemotherapy in Curatively Resected Colorectal Cancer with Liver Metastasis
ONCOLOGY 81 3-4:175~183,2011


DNA Methylation Predicts Recurrence From Resected Stage III Proximal Colon Cancer
CANCER 117 9:1847~1854,2011


Adenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis
BRITISH JOURNAL OF CANCER 106 1:53~60,2012


A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy
INVESTIGATIONAL NEW DRUGS 30 2:672~680,2012


Detection of liver metastases using gadoxetic-enhanced dynamic and 10- and 20-minute delayed phase MR imaging
JOURNAL OF MAGNETIC RESONANCE IMAGING 35 3:635~643,2012


Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis
Cancer Research and Treatment 44 1:43~49,2012


Response Evaluation in Patients With Colorectal Liver Metastases:RECIST Version 1.1 Versus Modified CT Criteria
AMERICAN JOURNAL OF ROENTGENOLOGY 199 4:809~815,2012


Perfusion MRI for the prediction of treatment response after preoperative chemoradiotherapy in locally advanced rectal cancer
EUROPEAN RADIOLOGY 22 8:1693~1700,2012


A phase i pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy
INVESTIGATIONAL NEW DRUGS 30 4:1501~1510,2012


Clinical and Cost Effectiveness of Bevacizumab + FOLFIRI Combination Versus FOLFIRI Alone as First-Line Treatment of Metastatic Colorectal Cancer in South Korea
CLINICAL THERAPEUTICS 34 6:1408~1419,2012


Treatment Outcome of Patients with Anaplastic Thyroid Cancer: A Single Center Experience
YONSEI MEDICAL JOURNAL 53 2:352~357,2012


Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial
CANCER CHEMOTHERAPY AND PHARMACOLOGY 69 1:91~97,2012


Implications of clinical risk score to predict outcomes of liver-confined metastasis of colorectal cancer
SURGICAL ONCOLOGY-OXFORD 21 3:e125~e130,2012


VIPoma that arose from the rectum in a 65-year-old male patient
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE 27 10:1385~1386,2012


Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience
BMC CANCER 12 1:471~471,2012


Quantitative analysis of ERK signaling inhibition in colon cancer cell lines using phospho-specific flow cytometry.
ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY 34 6:309~316,2012


The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY 27 1:e53~e59,2013


Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent
INVESTIGATIONAL NEW DRUGS 31 1:1~13,2013


Estimating the Adjuvant Chemotherapy Effect in Elderly Stage II and III Colon Cancer Patients in an Observational Study
JOURNAL OF SURGICAL ONCOLOGY 107 6:613~618,2013


Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors
SUPPORTIVE CARE IN CANCER 21 6:1751~1759,2013


Combination of CYP Inhibitor with MEK/ERK Inhibitor Enhances the Inhibitory Effect on ERK in BRAF Mutant Colon Cancer Cells
ANTICANCER RESEARCH 33 6:2499~2508,2013


Changing treatment patterns in elderly patients with resectable colon cancer
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 9 3:265~272,2013


Assessment of efficiency and safety of the comprehensive Chemotherapy Assistance Program for ordering oncology medications
INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS 82 6:504~513,2013


Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.
CANCER CHEMOTHERAPY AND PHARMACOLOGY 72 4:825~835,2013


Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma
CANCER CHEMOTHERAPY AND PHARMACOLOGY 72 4:853~860,2013


Prognostic Value of Mucinous Histology Depends on Microsatellite Instability Status in Patients with Stage III Colon Cancer Treated with Adjuvant FOLFOX Chemotherapy: A Retrospective Cohort Study
ANNALS OF SURGICAL ONCOLOGY 20 11:3407~3413,2013


Quantitation and pharmacokinetics of 1,4-diamino-2,3-dicyano-1,4-bis (2-aminophenylthio) butadiene (U0126) in rat plasma by liquid chromatography-tandem mass spectrometry
JOURNAL OF SEPARATION SCIENCE 36 2:239~245,2013

언론보도자료

게시물 리스트
번호 제목 첨부 등록일
1 [SBS 뉴스와생활경제] 세브란스병원, 암성 통증클리닉 운영 - 종양내과 신상준 교... 2010-11-05

처음페이지 이전 10개 1 다음 10 개 마지막페이지


 
2011/04/13 11:11 2011/04/13 11:11

카테고리

전체 (4)
프로필 (1)
언론보도 (1)
강좌,강연동영상 (2)

공지사항

달력

«   2017/08   »
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

태그목록

Archive